SCHEMBL1284567

SCHEMBL1284567

CC1(C)OB(c2ccc(N)cc2Cl)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
TSHR P16473 2/20 0.42
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
ALDH1A1 P00352 4/20 0.38
ALOX15 P16050 2/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 2/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LPL P06858 3/20 0.33
LIPG Q9Y5X9 3/20 0.33
CA9 Q16790 3/20 0.33
PDE7A Q13946 1/20 0.33
KDM4E B2RXH2 1/20 0.33
RAD52 P43351 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498572 1.00 CYP3A4 (0.42) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL29537826 0.86 CYP3A4 (0.42) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL12481678 0.86 CYP3A4 (0.42) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL28919694 0.81 CASP1 (0.39) CA1CA2ALDH1A1CASP1LPL
SCHEMBL15071862 0.81 TSHR (0.39) CYP3A4TSHRALDH1A1HSD17B10MAPT
SCHEMBL29407647 0.80 ALDH1A1 (0.43) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL16688104 0.80 LPL (0.46) CA1CA2LPLLIPGCA9
SCHEMBL58186 0.80 ALDH1A1 (0.43) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL462939 0.80 JAK2 (0.36) CYP3A4ALDH1A1ALOX15THRBHPGD
SCHEMBL28601719 0.79 LPL (0.36) CA1CA2ALDH1A1CASP1LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-04-28 US disclosed
US-20260049085-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. (US) 2026-02-19 US disclosed
EP-3774797-B1 HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF MERCK PATENT GMBH (DE) 2025-11-19 EP disclosed
US-20250276952-A1 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF CYTEIR THERAPEUTICS INC (US) 2025-09-04 US disclosed
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 US disclosed
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 US disclosed
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 US disclosed
WO-2024245193-A1 HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海艾力斯医药科技股份有限公司 2024-12-05 WO disclosed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US disclosed
WO-2024208315-A1 AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-10-10 WO disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
US-20110281842-A1 PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
WO-2011130628-A1 TREATMENT OF CANCERS HAVING K-RAS MUTATIONS CURIS, INC. (US) 2011-10-20 WO disclosed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 US disclosed
WO-2011083275-A1 ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 WO disclosed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US disclosed
WO-2010138879-A1 COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 HYDRA BIOSCIENCES, INC. (US) 2010-12-02 WO disclosed
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 US disclosed
EP-1778233-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2007-05-02 EP disclosed
WO-2006019716-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 CYP3A4 50/4885TSHR 2678/4885CA1 4829/4885
US-20110281842-A1 PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB CYP3A4 2462/4885TSHR 2582/4885CA1 3759/4885
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS CDK1, CDK11A, CDK3 CYP3A4 4370/4885TSHR 3696/4885CA1 4435/4885
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 CYP3A4 4247/4885TSHR 89/4885CA1 3601/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB CYP3A4 4747/4885TSHR 2427/4885CA1 2909/4885
US-20250276952-A1 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF ABAT, PYGB, MAPT CYP3A4 48/4885TSHR 2473/4885CA1 681/4885
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof MAPT, MAP2, MAP1B CYP3A4 4217/4885TSHR 3602/4885CA1 3811/4885
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 CYP3A4 594/4885TSHR 2158/4885CA1 1990/4885
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CYP3A4 4566/4885TSHR 4603/4885CA1 1132/4885
US-20260049085-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 CYP3A4 736/4885TSHR 158/4885CA1 207/4885
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB CYP3A4 683/4885TSHR 4208/4885CA1 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.